Jan M. Middeke

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications

Next-generation synthetic trials in hematology with generative artificial intelligence.

Next-generation synthetic trials in hematology with generative artificial intelligence.

Journal: Leukemia
Published: July 17, 2026

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Journal: Annals of hematology
Published: July 03, 2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Journal: Haematologica
Published: April 20, 2026

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal: Journal of thrombosis and haemostasis : JTH
Published: April 15, 2026

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Journal: British journal of haematology
Published: March 04, 2026

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Journal: Bone marrow transplantation
Published: February 06, 2026

Artificial intelligence-generated synthetic data for cancer research and clinical trials.

Artificial intelligence-generated synthetic data for cancer research and clinical trials.

Journal: Nature reviews. Cancer
Published: January 19, 2026

Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.

Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.

Journal: European journal of haematology
Published: December 17, 2025

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

Journal: Annals of hematology
Published: October 08, 2025

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Journal: The Lancet. Haematology
Published: September 01, 2025

Artificial intelligence for risk assessment and outcome prediction in malignant haematology.

Artificial intelligence for risk assessment and outcome prediction in malignant haematology.

Journal: British journal of haematology
Published: August 29, 2025

Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases.

Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases.

Journal: Annals of hematology
Published: August 27, 2025
Showing 1-12 of 131

Last Updated: 09/26/2026